Ardelyx

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Ardelyx and other ETFs, options, and stocks.

About ARDX

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. 

CEO
Michael G. Raab
CEOMichael G. Raab
Employees
395
Employees395
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
2007
Founded2007
Employees
395
Employees395

ARDX Key Statistics

Market cap
1.81B
Market cap1.81B
Price-Earnings ratio
-31.15
Price-Earnings ratio-31.15
Dividend yield
Dividend yield
Average volume
3.09M
Average volume3.09M
High today
$7.84
High today$7.84
Low today
$7.31
Low today$7.31
Open price
$7.75
Open price$7.75
Volume
2.82M
Volume2.82M
52 Week high
$8.40
52 Week high$8.40
52 Week low
$3.21
52 Week low$3.21

Stock Snapshot

Ardelyx(ARDX) stock is priced at $7.36, giving the company a market capitalization of 1.81B. It carries a P/E multiple of -31.15.

As of 2026-02-04, Ardelyx(ARDX) stock has fluctuated between $7.31 and $7.84. The current price stands at $7.36, placing the stock +0.7% above today's low and -6.1% off the high.

The Ardelyx(ARDX)'s current trading volume is 2.82M, compared to an average daily volume of 3.09M.

In the last year, Ardelyx(ARDX) shares hit a 52-week high of $8.40 and a 52-week low of $3.21.

In the last year, Ardelyx(ARDX) shares hit a 52-week high of $8.40 and a 52-week low of $3.21.

ARDX News

Simply Wall St 5d
How Ardelyx’s Phase 3 IBSRELA Trial in Chronic Constipation Has Changed Its Investment Story At Ardelyx

Ardelyx recently dosed the first patient in ACCEL, a Phase 3, 26‑week, randomized, double‑blind, placebo‑controlled trial of IBSRELA (tenapanor) in about 700 ad...

How Ardelyx’s Phase 3 IBSRELA Trial in Chronic Constipation Has Changed Its Investment Story At Ardelyx
TipRanks 7d
Ardelyx price target raised to $13 from $10 at TD Cowen

TD Cowen raised the firm’s price target on Ardelyx (ARDX) to $13 from $10 and keeps a Buy rating on the shares. The firm updated its model ahead of Q4 results....

TipRanks 7d
Ardelyx: Commercial Momentum, Expanded Ibsrela Opportunity, and Strengthened IP Underpin Buy Rating

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Ardelyx, with a price target of $17.00. Claim 50% Off TipRanks Premium Unlo...

Analyst ratings

100%

of 13 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own ARDX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.